Clinical trials: Anxiety, Generalized
Major Depressive Disorder, Generalized Anxiety Disorder
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time.
- Trial name
- NCT05016050
- Testing
- HPDT-DA-013
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Happify Inc.
Anxiety Disorder, Anxiety Disorders
Study Of Generalized Anxiety Disorder
This study is designed to evaluate the efficacy and safety in Generalized Anxiety Disorder patients
- Trial name
- NCT00135525
- Testing
- Paroxetine
- Sponsor
- GlaxoSmithKline
Generalized Anxiety Disorder
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder.
- Trial name
- NCT00658372
- Testing
- PD 0332334, Paroxetine
- Where
- 33 sites in United States, Hungary and 2 more
- Volunteers
- 360 people
- Sponsor
- Pfizer
Generalized Anxiety Disorder
Escitalopram in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to escitalopram during the…
- Trial name
- NCT00902564
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Anxiety Disorders
Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD).
- Trial name
- PLATINUM (NCT00314210)
- Testing
- Quetiapine SR
- Where
- 114 sites in United States, Australia and 9 more
- Volunteers
- 575 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder
This is a single dose study to investigate the efficacy, safety, tolerability and the PK, of SYT-510 in participants who meet diagnostic criteria of GAD.
- Trial name
- NCT07478744
- Testing
- SYT-510
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Synendos Therapeutics AG
Anxiety
Clinical and Cost Effectiveness of Alpha-Stim AID CES
This is a single-centre research study in patients seen within an NHS Improving Access to Psychological Interventions (IAPT) service with suspected generalised anxiety disorder (GAD).
- Trial name
- NCT02901080
- Testing
- Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire
- Where
- United Kingdom
- Volunteers
- 161 people
- Sponsor
- Electromedical Products International, Inc.
Insomnia, Generalized Anxiety Disorder
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder.
- Trial name
- NCT00235508
- Testing
- Eszopiclone (Lunesta)
- Where
- 64 sites in United States
- Volunteers
- 420 people
- Sponsor
- Sumitomo Pharma America, Inc.
Generalized Anxiety Disorder
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.
- Trial name
- NCT00658008
- Testing
- PD 0332334, Paroxetine
- Where
- 52 sites in United States, Hungary and 3 more
- Volunteers
- 501 people
- Sponsor
- Pfizer
Treatment Adherence, Generalized Anxiety
Cerina-A Pilot Randomized Controlled Trial
The goal of this pilot Randomized Controlled Trial is twofold: 1) To learn about the feasibility and usefulness of a mobile application for generalised anxiety symptoms (Cerina); 2) To test the preliminary effects of Cerina in…
- Conditions
- Treatment Adherence, Generalized Anxiety, Treatment Adherence and Compliance
- Trial name
- Cerina (NCT06146530)
- Testing
- Treatment
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- Cerina Therapeutics
Generalized Anxiety Disorder
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
- Trial name
- NCT00735267
- Testing
- PD 0332334
- Where
- 93 sites in United States
- Volunteers
- 468 people
- Sponsor
- Pfizer
Generalized Anxiety Disorder
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
1. To estimate the effects of multiple doses of PD 0332334 on the elimination of a single dose of metformin from the body 2. To estimate the effects of multiple doses of metformin on the elimination of a single dose of PD 0332334…
- Trial name
- NCT00809536
- Testing
- Metformin, PD 0332334
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of two fixed doses (100 mg and 30 mg once daily) of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00390533
- Testing
- Saredutant
- Where
- 2 sites in United States, Australia
- Volunteers
- 428 people
- Sponsor
- Sanofi
Major Depressive Disorder, Generalized Anxiety
Scaling Mental Healthcare in COVID-19 With Voice Biomarkers
This study aims to advance research on group sessions for mental health. The first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and…
- Trial name
- NCT04510519
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Generalized Anxiety Disorder
Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy and safety of comparative high dose Tandospirone Citrate in the treatment of patients with generalized anxiety disorder.
- Trial name
- TACGAD (NCT01614041)
- Testing
- Usual dose treatment of Tandospirone, Comparative high dose of tandospirone treatment
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Autism Spectrum Disorder, Depression - Major Depressive Disorder
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
This study investigates whether AI-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (ADHD)…
- Conditions
- Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
- Trial name
- MINDAIM (NCT06792175)
- Testing
- Solicue Machine Learning Models, Mercuria Machine Learning Models
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Psyrin Inc.
Anxiety Disorders
Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy.
The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment.
- Trial name
- NCT00086112
- Testing
- risperidone oral tablets
- Volunteers
- 301 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Generalized Anxiety
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with generalized anxiety disorder.
- Trial name
- NCT00417118
- Testing
- Saredutant, Escitalopram
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 365 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder (GAD)
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- NCT06846320
- Testing
- ABBV-932, Antidepressant Therapy (ADT)
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- AbbVie
Generalized Anxiety Disorder, Panic Disorder
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
An 8-week, open-label trial in 848 subjects at 212 sites to compare time to response in symptoms of anxiety in subjects treated with Niravam™ and a newly prescribed Selective Serotonin Reuptake Inhibitor (SSRI)or Serotonin and…
- Trial name
- NCT00266409
- Testing
- Niravam, SSRI/SNRI
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- UCB Pharma